Pill may replace shots for elderly blood cancer patients
NCT ID NCT04806906
First seen May 13, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This study tested an oral version of the drug azacitidine (CC-486) in 11 elderly patients with higher-risk myelodysplastic syndromes (MDS) who had already improved with injectable azacitidine. The goal was to see if the oral pill could safely maintain that improvement and make treatment easier by avoiding frequent hospital visits. The study focused on safety, maintaining response, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AOU Careggi- University of Florence
Florence, 50134, Italy
Conditions
Explore the condition pages connected to this study.